{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:41:29Z","timestamp":1783528889189,"version":"3.55.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Eosinophilic esophagitis (EoE), a chronic immune-mediated inflammatory disorder, is increasingly recognized globally. Budesonide, a topical corticosteroid, is widely used for EoE; but its efficacy and safety profile require comprehensive evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of budesonide in EoE through an updated systematic review and meta-analysis of randomized controlled trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Following PRISMA guidelines and AMSTAR guidelines, we searched PubMed, EMBASE, and Google Scholar for RCTs comparing budesonide with placebo in EoE patients (conception to January 2025). A GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach was applied to rate the certainty of evidence across key outcomes. Primary outcomes included histologic response (\u226415 eosinophils\/high-power field), clinical symptom improvement, and safety. Data were pooled using random\/fixed-effects models, with sensitivity analyses to address heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Eleven RCTs (1089 participants) were included. Budesonide significantly improved histologic remission (RR: 26.85; 95% CI: 13.72\u201352.56;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.00001) and reduced peak eosinophil counts (SMD: \u22121.08; 95% CI: \u22121.40 to 0.77;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.00001). Clinical response (RR: 1.58; 95% CI: 1.03\u20132.42;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.04) and dysphagia symptom scores (SMD: \u22120.29; 95% CI: \u22120.49 to 0.09;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004) also favored budesonide. However, fibrosis scores showed no significant improvement (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.48). Adverse events were comparable to placebo overall (RR: 1.01; 95% CI: 0.82\u20131.24), though infections were more frequent with budesonide (RR: 2.14; 95% CI: 1.20\u20133.80;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009). Transient cortisol suppression occurred in sensitivity analyses (SMD: \u22120.41; 95% CI: \u22120.66 to 0.16;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). Most infections were localized (e.g., oropharyngeal candidiasis) and rarely required treatment discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Budesonide effectively induces histologic and clinical remission in EoE but does not reverse fibrosis. While generally safe, long-term adrenal monitoring is warranted due to cortisol suppression. GRADE evaluation suggested moderate-to-high certainty for efficacy outcomes and moderate certainty for safety outcomes. Persistent symptoms in fibrostenotic disease highlight the need for adjunct therapies. Future research should optimize dosing regimens and evaluate combination strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000004577","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T15:00:07Z","timestamp":1765465207000},"page":"760-770","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of budesonide for eosinophilic esophagitis: an updated systematic review and meta-analysis"],"prefix":"10.1097","volume":"88","author":[{"given":"Kanza","family":"Farhan","sequence":"first","affiliation":[{"name":"Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6908-0836","authenticated-orcid":false,"given":"Muhammad Burhan","family":"Tariq","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Usama","family":"Shahid","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2304-2196","authenticated-orcid":false,"given":"Barka","family":"Sajid","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabeya","family":"Farid","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mirza","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3067-560X","authenticated-orcid":false,"given":"Izere","family":"Salomon","sequence":"additional","affiliation":[{"name":"Department of General Medicine and Surgery, University of Rwanda, college of medicine and health sciences, Kigali, Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0973-3972","authenticated-orcid":false,"given":"Muskan","family":"Tanveer","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"R1-20260514","doi-asserted-by":"crossref","first-page":"3\u201320","DOI":"10.1016\/j.jaci.2011.02.040","article-title":"Eosinophilic esophagitis: updated consensus recommendations for children and adults","volume":"128","author":"Liacouras","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R3-20260514","first-page":"1239\u201345","article-title":"Population-based incidence and prevalence of eosinophilic esophagitis","volume":"13","author":"Jensen","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R4-20260514","first-page":"1429\u201336","article-title":"Escalating incidence of eosinophilic esophagitis: a 20-year prospective population-based study","volume":"66","author":"Hruz","year":"2011","journal-title":"Allergy"},{"key":"R5-20260514","first-page":"291\u2013311","article-title":"Clinical manifestations and diagnosis of eosinophilic esophagitis","volume":"43","author":"Moawad","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"key":"R6-20260514","doi-asserted-by":"crossref","first-page":"536\u201347","DOI":"10.1172\/JCI26679","article-title":"Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis","volume":"116","author":"Blanchard","year":"2006","journal-title":"J Clin Invest"},{"key":"R7-20260514","doi-asserted-by":"crossref","first-page":"1230\u201336","DOI":"10.1053\/j.gastro.2013.08.015","article-title":"Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner","volume":"145","author":"Schoepfer","year":"2013","journal-title":"Gastroenterology"},{"key":"R8-20260514","first-page":"1234","article-title":"Efficacy of dietary interventions for inducing histologic remission in pediatric eosinophilic esophagitis","volume":"152","author":"Kagalwalla","year":"2017","journal-title":"Gastroenterology"},{"key":"R9-20260514","first-page":"2329\u201341","article-title":"Role of budesonide in the treatment of eosinophilic esophagitis","volume":"13","author":"Dellon","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"R10-20260514","first-page":"581\u201392","article-title":"Budesonide oral suspension in eosinophilic esophagitis: a randomized, double-blind trial","volume":"150","author":"Miehlke","year":"2016","journal-title":"Gastroenterology"},{"key":"R11-20260514","first-page":"703\u201310","article-title":"Long-term budesonide maintenance treatment for eosinophilic esophagitis","volume":"128","author":"Straumann","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R12-20260514","doi-asserted-by":"crossref","first-page":"1842\u201349","DOI":"10.1016\/j.cgh.2014.05.021","article-title":"Efficacy and safety of budesonide in children with eosinophilic esophagitis: a randomized, double-blind, placebo-controlled trial","volume":"13","author":"Gupta","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R13-20260514","first-page":"1278\u201391","article-title":"Efficacy of topical corticosteroids in eosinophilic esophagitis: a systematic review and meta-analysis","volume":"111","author":"Lucendo","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R14-20260514","article-title":"Transparency in the reporting of artificial intelligence\u2014the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci Rev"},{"key":"R15-20260514","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R16-20260514","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R17-20260514","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomized trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R18-20260514","first-page":"1102\u201312","article-title":"Maintenance therapy with budesonide in adult eosinophilic esophagitis","volume":"145","author":"Straumann","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R19-20260514","first-page":"397\u2013404","article-title":"Budesonide oral suspension for the treatment of eosinophilic esophagitis in children: a randomized controlled trial","volume":"60","author":"Schlag","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R20-20260514","first-page":"142\u201355","article-title":"Long-term efficacy and safety of budesonide orodispersible tablets in adults with eosinophilic esophagitis","volume":"54","author":"Hirano","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-20260514","first-page":"e00064","article-title":"Optimizing budesonide therapy for eosinophilic esophagitis: formulation, dosing, and delivery","volume":"10","author":"Lucendo","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"R22-20260514","first-page":"1237\u201345","article-title":"Budesonide oral suspension versus placebo in pediatric eosinophilic esophagitis","volume":"14","author":"Dellon","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R23-20260514","first-page":"130\u201336","article-title":"Oral viscous budesonide for induction and maintenance treatment of eosinophilic esophagitis","volume":"128","author":"Hruz","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R24-20260514","first-page":"550\u201356","article-title":"Safety and efficacy of oral viscous budesonide for eosinophilic esophagitis in children and adolescents","volume":"59","author":"Gupta","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R25-20260514","first-page":"667\u201377","article-title":"Comparative efficacy of budesonide formulations in eosinophilic esophagitis: a systematic review","volume":"8","author":"Miehlke","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R26-20260514","first-page":"1057\u201371","article-title":"Budesonide orodispersible tablets for eosinophilic esophagitis: a comprehensive review","volume":"81","author":"Arias","year":"2021","journal-title":"Drugs"},{"key":"R27-20260514","first-page":"987\u201395","article-title":"Oral viscous budesonide for pediatric eosinophilic esophagitis: a randomized controlled trial","volume":"145","author":"Hirano","year":"2013","journal-title":"Gastroenterology"},{"key":"R28-20260514","first-page":"1246\u201354","article-title":"Oral viscous budesonide for eosinophilic esophagitis: dose optimization and safety assessment","volume":"14","author":"Miehlke","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R29-20260514","first-page":"110\u201316","article-title":"Correlation between histologic and symptom response in eosinophilic esophagitis","volume":"11","author":"Dellon","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R30-20260514","first-page":"1459\u201366","article-title":"Long-term efficacy of topical corticosteroids in pediatric eosinophilic esophagitis","volume":"10","author":"Kagalwalla","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R31-20260514","first-page":"1055\u201361","article-title":"Clinical and endoscopic outcomes with budesonide in eosinophilic esophagitis","volume":"65","author":"Straumann","year":"2010","journal-title":"Allergy"},{"key":"R32-20260514","first-page":"1278\u201391","article-title":"Budesonide in the treatment of eosinophilic esophagitis: systematic review","volume":"111","author":"Hirano","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"R33-20260514","first-page":"1541\u201349","article-title":"Clinical response and esophageal remodeling after budesonide therapy","volume":"13","author":"Lucendo","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R34-20260514","first-page":"659\u201366","article-title":"Endoscopic dilation and anti-inflammatory therapy for fibrostenotic eosinophilic esophagitis","volume":"79","author":"Dellon","year":"2014","journal-title":"Gastrointest Endosc"},{"key":"R35-20260514","first-page":"120\u201328","article-title":"Long-term management of eosinophilic esophagitis with endoscopic dilation and topical steroids","volume":"11","author":"Hirano","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R36-20260514","first-page":"110\u201319","article-title":"Safety profile of budesonide oral suspension in eosinophilic esophagitis","volume":"37","author":"Straumann","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R37-20260514","first-page":"227\u201332","article-title":"Cortisol suppression after oral viscous budesonide therapy in eosinophilic esophagitis","volume":"61","author":"Lucendo","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R38-20260514","first-page":"247\u201353","article-title":"Adrenal function monitoring during long-term budesonide therapy for eosinophilic esophagitis","volume":"138","author":"Miehlke","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"R39-20260514","first-page":"2002\u201307","article-title":"Recurrence of eosinophilic esophagitis after cessation of topical steroid therapy","volume":"12","author":"Dellon","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R40-20260514","first-page":"1101\u201308","article-title":"Maintenance therapy with low-dose budesonide in eosinophilic esophagitis","volume":"16","author":"Hirano","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R41-20260514","first-page":"42\u201348","article-title":"Adrenal suppression in pediatric eosinophilic esophagitis treated with budesonide","volume":"63","author":"Lucendo","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R42-20260514","first-page":"110\u201316","article-title":"Long-term safety of budesonide in adult eosinophilic esophagitis","volume":"9","author":"Straumann","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R43-20260514","first-page":"2008\u201314","article-title":"Disease recurrence and maintenance therapy in eosinophilic esophagitis","volume":"12","author":"Dellon","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R44-20260514","first-page":"341\u201349","article-title":"Emerging therapies for eosinophilic esophagitis: biologics and novel corticosteroids","volume":"36","author":"Hirano","year":"2020","journal-title":"Curr Opin Gastroenterol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:00:25Z","timestamp":1778749225000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004577","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"2025-05-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}